Updates in Heart Failure (HF) 2016: ACC / AHA and ESC

Size: px
Start display at page:

Download "Updates in Heart Failure (HF) 2016: ACC / AHA and ESC"

Transcription

1 Updates in Heart Failure (HF) 2016: ACC / AHA and ESC Patrick McBride, MD, MPH Professor of Medicine & Family Medicine, UW School of Medicine and Public Health Special thanks to: Clyde W. Yancy, MD, MSc Professor of Medicine, Chief, Cardiology Northwestern University, Deputy Editor, JAMA Cardiology Patrick E. McBride, MD, MPH Professor of Medicine and Family Medicine Associate Director, Preventive Cardiology Interim, Associate Dean for Faculty Affairs Senior Research Director, Research Networks ICTR I have no conflicts of interest to disclose 1

2 Objectives: The diagnosis and treatment of HFrEF* New Epidemiology 2016 Prevention New Guidelines New Therapies New Phenotype *HFrEF = heart failure reduced ejection fraction From: A Contemporary Appraisal of the Heart Failure Epidemic in Olmsted County, Minnesota, 2000 to 2010 JAMA Intern Med. 2015;175(6): doi: /jamainternmed Figure Legend: Temporal Trends in Heart Failure Incidence Rates Overall and by Reduced or Preserved Ejection Fraction Among Women and Men in Olmsted County, Minnesota, 2000 to 2010Yearly rates (smoothed using 3-year moving average) per persons have been standardized by the direct method to the age distribution of the US population in HFpEF indicates heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction. Copyright 2016 American Medical Association. All rights reserved. 2

3 A Contemporary Appraisal of the HF Epidemic Age and sex-specific incidence of heart failure has declined 315/100,000 to 219/100,000 Rate reduction of 37.5% Incidence decline was greater for HFrEF 45.1% vs. HFpEF-27.9% Risk for CV death was lower for HFpEFbut the same for non-cv death Hospitalizations have increased 34% Most hospitalizations, 63%, were due to non-cardiovascular causes Thus today s epidemic of heart failure is defined by a marked increase in hospitalizations, predominance of non-cv death rate, and persistence and predominance of HFpEF Roger VL et al. JAMAIntern Med. 2015; April 20. Stages, Phenotypes and Treatment of HF 3

4 The treatment of HFrEF; Update New Epidemiology Prevention New Guidelines New Therapies New Phenotype Prevalence and prognostic significance of HF Stages Survival (years) Ammar et al. Circulation 2007; 115:1563 4

5 Comparison of short-term vs lifetime cumulative risks of CHF for men and women at selected index ages ONE IN FIVE INDIVIDUALS WILL DEVELOP HF FRAMINGHAM Donald M. Lloyd-Jones et al Circulation 2002;106:3068 Lifetime risk for HF; indexed to blood pressure & sex 5

6 STAGE A HF: Hypertension as a Risk Factor for HF in African Americans Bibbins-Domingo et al. N Engl J Med. 360(12): Incidence of heart failure in young Americans Bibbins-Domingo et al. New England Journal of Medicine. 360(12):

7 SPRINT Hypertension Trial Study Design: Randomized Single Blind Primary Outcome Measures: First occurrence of a myocardial infarction (MI), acute coronary syndrome (ACS), stroke, heart failure (HF), or CVD death [ Time Frame: 6 years ] Secondary Outcome Measures: All-cause mortality ; Development of end stage renal disease (ESRD), Dementia, Decline in cognitive function, Small vessel cerebral ischemic disease Estimated Enrollment: 9250 Increased CV risk as defined by SPRINT: clinical or subclinical cardiovascular disease other than stroke; chronic kidney disease, excluding polycystic kidney disease, with an estimated glomerular filtration rate (egfr) of 20 to less than 60 ml per minute per 1.73 m 2 of body-surface area, calculated with the use of the four-variable Modification of Diet in Renal Disease equation; a 10-year risk of cardiovascular disease of 15% or greater on the basis of the Framingham risk score; or an age of 75 years or older 7

8 Systolic Blood Pressure in the Two Treatment Groups over the Course of the Trial The SPRINT Research Group. N Engl J Med 2015;373: Primary Outcome and Death from Any Cause The SPRINT Research Group. N Engl J Med 2015;373:

9 Primary and Secondary Outcomes and Renal Outcomes 38% RR TheSPRINT Research Group. N Engl J Med 2015;373: The diagnosis and treatment of HFrEF New Epidemiology Prevention New Guidelines New Therapies New Phenotype 9

10 Stages, Phenotypes and Treatment of HF Yancy, C. Jessup M, Bozkurt B. et al. JACC 2013 Pharmacologic Treatment for Stage C HFrEF Yancy, C et al. JACC

11 New Guidelines Have Emerged RAASi in Heart Failure and Post-MI LV Dysfunction Post-MI Low EF Mild-Mod CHF Low EF CHF Severe HF CHF Preserved EF ACEi 1 AIRE SAVE SOLVD CONSENSUS PEP-CHF (perindopril) MRA EPHESUS 1 (eplerenone) EMPHASIS 1 (eplerenone) RALES 1 (spironolactone) TOPCAT 2 (spironolactone) ARB 1 OPTIMAAL VALIANT ELITE-II HEALL VAL-HeFT CHARM CHARM-Preserved I-PRESERVE ARNI 3 PARADIGM-HF (LCZ-696) RAASi=renin-angiotensin-aldosterone inhibitor; MI=myocardial infarction; EF: ejection fraction; CHF=chronic heart failure; ACEi=angiotensin-converting enzyme inhibitor; MRA=mineralocorticoid receptor antagonist; ARB=angiotensin II receptor blocker; ARNI=angiotensin receptor-neprilysin inhibitor. 1. Mentz RJ, et al. Int J Cardiol. 2013:167: Pitt B, et al. N Engl J Med. 2014;370(15): McMurray JJV, et al. N Engl J Med 2014;371:

12 RAAS inhibition ACE-I & ARB

13 ARNI 2016 ARNI (Harm)

14 Ivabradine 2016 ESC HF Guidelines

15 ESC HFrEF Treatment Algorithm The treatment of HFrEF: Update New Epidemiology Prevention New Guidelines New Therapies New Phenotype 15

16 Effects of Neprilysin Inhibition in Heart Failure Endogenous vasoactive peptides (natriuretic peptides, adrenomedullin, bradykinin, substance P, calcitonin gene-related peptide) Neurohormonal activation Vascular tone Cardiac fibrosis, hypertrophy Na+ retention Neprilysin Neprilysin inhibition Inactive metabolites McMurray JJV, et al. N Engl J Med. 2014;371: PARADIGM-HF: Primary Endpoint of CV Death or Heart Failure Hospitalization Cumulative Probability Number at Risk Sac/Val Enalapril Number needed to treat = 21 Enalapril 1117 events (26.5%) Days since Randomization HR 0.80 (95% CI, ), p< Sac/Val 914 events (21.8%) Sac/Val = Sacubitril/Valsartan. McMurray JJV, et al. N Engl J Med. 2014;371:

17 PARADIGM-HF: Effect of Sac/Val vs. Enalapril on the Primary Endpoint and Its Components Sac/Val (n=4187) Enalapril (n=4212) Hazard Ratio (95% CI) p- Value Primary endpoint 914 (21.8%) 1117 (26.5%) 0.80 ( ) <0.001 Cardiovascular death 558 (13.3%) 693 (16.5%) 0.80 ( ) <0.001 Hospitalization for heart failure 537 (12.8%) 658 (15.6%) 0.79 ( ) <0.001 Sac/Val = Sacubitril/Valsartan. McMurray JJV, et al. N Engl J Med. 2014;371: Sac/Val vs. Enalapril on Primary Endpoint and on CV Death by Subgroups Subgroup All Patients Age <65 years 65 years Sex Male Female NYHA Class I or II III or IV Estimated GFR <60 ml/min/1.73 m 2 60 ml/min/1.73 m 2 Ejection fraction 35% >35% NT-proBNP Median >Median Hypertension No Yes Prior use of ACE inhibitor No Yes Prior use of aldosterone antagonist No Yes Prior hospitalization for heart failure No Yes Sac/Val No. Enalapril Primary Endpoint Hazard Ratio (95% CI) p-value for Interaction Death from Cardiovascular Causes Hazard Ratio p-value for (95% CI) Interaction Sac/Val Better Enalapril Better McMurray JJV, et al. N Engl J Med. 2014;371: Sac/Val Better Enalapril Better 17

18 PARADIGM-HF: Adverse Events Prospectively identified adverse events Sac/Val (n=4187) Enalapril (n=4212) p- Value Symptomatic hypotension 14.0% 9.2% <0.001 Serum potassium > 6.0 mmol/l 4.3% 5.6% Serum creatinine 2.5 mg/dl 3.3% 4.5% Cough 11.3% 14.3% <0.001 Discontinuation for adverse event 10.7% 12.3% 0.03 Discontinuation for hypotension 0.9% 0.7% 0.38 Discontinuation for hyperkalemia 0.3% 0.4% 0.56 Discontinuation for renal impairment 0.7% 1.4% Angioedema (adjudicated) Medications, no hospitalization 6 (0.1%) 4 (0.1%) 0.52 Hospitalized; no airway compromise 3 (0.1%) 1 (<0.1%) 0.31 Airway compromise 0 0 McMurray JJV, et al. N Engl J Med. 2014;371: Brand name Indication Dosage Renal/hepatic impairment Switching from an ACE inhibitor Contraindications Side effects New FDA-Approved Sacubitril / Valsartan Sacubitril/Valsartan Entresto The fixed-dose combination of the neprilysin inhibitor sacubitril and the ARB valsartan is indicated to reduce the risk of CV death and HF hospitalization in patients with HF with reduced ejection fraction. Start with 49/51 mg twice daily. Double the dose after 2 4 weeks as tolerated to maintenance dose of 97/103 mg twice daily. For patients not currently taking an ACEI or ARB, or for those with severe renal impairment (egfr <30 ml/min/1.73 m 2 ) or moderate hepatic impairment, start with 24/26 mg twice daily. Stop ACE inhibitor for 36 hours before starting treatment. History of angioedema related to previous ACE inhibitor or ARB, concomitant use of ACE inhibitors, concomitant use of aliskiren in patients with diabetes. WARNING pregnancy, hyperkalemia. Hypotension, hyperkalemia, cough, dizziness, renal failure, and angioedema (0.5% Sac/Val vs. 0.2% Enalapril). Accessed October 20,

19 Practical Points on Use of Sacubitril / Valsartan Starting dose is 24 / 26 mg twice daily, unless patient is currently tolerating full dose ACEI or ARB in which case start 49 / 51 mg twice daily Target dose is 97 / 103 mg twice daily After 2-4 weeks up-titrate to next dose with ultimate goal to achieve target dose Monitor SBP, renal function and K as you would with ACEI or ARB use Space out dosing from other vasoactive medications if needed Adjust diuretics doses based on volume status Ivabradine Acts by inhibiting the If channel, present in the cardiac SA node Reduces elevated HR SA node Evaluated as treatment of HFrEF who have a resting HR of at least 70 beats per minute, in sinus rhythm, and who are also taking the highest tolerable dose of a beta blocker DiFrancesco D. Curr Med Res Opin. 2005;21:

20 SHIFT Study: Primary Endpoint of CV Death or Hospitalization for Worsening HF Patients with Primary Endpoint (%) Ivabradine (n=3241) Placebo (n=3264) Placebo 937 events (29%) Ivabradine 793 events (24%) HR 0.82 (95% CI, ) p< ARR = 5%, NNT = Months 18% Swedberg K, et al. Lancet. 2010;376: SHIFT Study: Effect of Ivabradine on Outcomes Endpoint Ivabradine (n=3241) Placebo (n=3264) HR p-value Primary endpoint 24% 29% 0.82 < All-cause mortality 16% 17% Death from HF 3% 5% All-cause hospitalization 38% 42% Any CV hospitalization 30% 34% CV death, hospitalization for worsening HF, or hospitalization for non-fatal MI 25% 30% 0.82 < Swedberg K, et al. Lancet. 2010;376:

21 New FDA-Approved Ivabradine Ivabradine Brand name Indication Dosage Contraindications Corlanor To reduce the risk of hospitalization for worsening HF in patients with stable, symptomatic chronic HF with LVEF 35% who are in sinus rhythm with resting HR 70 bpm and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use. Start with 5 mg twice daily. After 2 weeks of treatment, adjust dose based on HR. Max is 7.5 mg twice daily. In patients with conduction defects or in whom bradycardia could lead to hemodynamic compromise, start with 2.5 mg twice daily. Acute decompensated HF; BP <90/50 mmhg; sick sinus syndrome or third-degree AV block, unless a functioning demand pacemaker is present; resting HR < 60 bpm prior to treatment; severe hepatic impairment; pacemaker dependence. WARNING fetal toxicity. Side effects Occurring in 1% of patients are bradycardia, hypertension, atrial fibrillation, and luminous phenomena (phosphenes). Accessed October 20, Practical Use of Ivabradine Starting dose is 5 mg twice daily Target HR is bpm After 2 weeks: If HR >60 bpm: Increase dose to 7.5 mg twice daily (Max dose) If HR bpm: Maintain initial dose If HR <50 bpm or symptomatic bradycardia: Lower dose to 2.5 mg twice daily If HR <50 bpm or symptomatic bradycardia and dose is 2.5 mg twice daily: Discontinue 21

22 Pharmacologic Treatment for Stage C HFrEF Strategies: Disease Management Remote PA monitoring Process Improvement Patient Education Frailty Assessment Palliative Care Genetic Counseling? Valsartan/Sacubutril? Ivabradine From: Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure JAMA Cardiol. Published online June 22, doi: /jamacardio Table Title: Demonstrated Benefits of Evidence-Based Therapies for Patients With Heart Failure and Reduced Ejection Fraction Date of download: 7/11/2016 Copyright 2016 American Medical Association. All rights reserved. 22

23 The treatment of HFrEF: Update New Epidemiology Prevention New Guidelines New Therapies New Classification A new classification? ESC HF GUIDELINES

24 Definition of Heart Failure- ACC/AHA 2013 Classification I. Heart Failure with Reduced Ejection Fraction (HFrEF) Ejection Fraction Description 40% Also referred to as systolic HF. Randomized clinical trials have mainly enrolled patients with HFrEF and it is only in these patients that efficacious therapies have been demonstrated to date. II. Heart Failure with Preserved Ejection Fraction (HFpEF) 50% Also referred to as diastolic HF. Several different criteria have been used to further define HFpEF. The diagnosis of HFpEF is challenging because it is largely one of excluding other potential noncardiac causes of symptoms suggestive of HF. To date, efficacious therapies have not been identified. a. HFpEF, Borderline 41% to 49% These patients fall into a borderline or intermediate group. Their characteristics, treatment patterns, and outcomes appear similar to those of patient with HFpEF. b. HFpEF, Improved >40% It has been recognized that a subset of patients with HFpEF previously had HFrEF. These patients with improvement or recovery in EF may be clinically distinct from those with persistently preserved or reduced EF. Further research is needed to better characterize these patients. Yancy C et al, JACC 2013 Taking the failure out of HF ***We can prevent the progression of HF Greater use of PREVENTION, DIAGNOSIS, imaging, prognosis & treatment ; early introduction of RAAS inhibitors Quality Improvement Still with untapped effectiveness MAXIMIZE THERAPY! Device therapy (ICD/CRT) as indicated New drug therapies- ARNI (Sacubitril / Valsartan); Ivabradine Personalized Therapy driven by Pharmacogenomics -Future? Stem cells Gene Transfer; Growth Factors, Gene Editing 24

25 Thank You! From: Characteristics and Outcomes of Adult Outpatients With Heart Failure and Improved or Recovered Ejection Fraction JAMA Cardiol. Published online July 06, doi: /jamacardio Figure Legend: Kaplan-Meier Curves, Adjusted for Age and Sex, Across the 3 Heart Failure GroupsThe stratified log-rank χ 2 2 was 15.0 (P <.001) for difference in mortality between groups. HFpEF indicates heart failure with preserved ejection fraction; HFrecEF, heart failure with recovered ejection fraction; and HFrEF, heart failure with reduced ejection fraction. Date of download: 7/11/2016 Copyright 2016 American Medical Association. All rights reserved. 25

Beyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015

Beyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015 Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid

More information

Tuesday October 18, :00pm 2:00pm Central Presenter: Clyde W. Yancy, MD, MSc

Tuesday October 18, :00pm 2:00pm Central Presenter: Clyde W. Yancy, MD, MSc Tuesday October 18, 2016 1:00pm 2:00pm Central Presenter: Clyde W. Yancy, MD, MSc Amgen Cardiovascular proudly sponsors Heart Science Amplified: An Online Speaker Series and Get With The Guidelines -Heart

More information

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies

More information

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17 Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies

More information

Treating HF Patients with ARNI s Why, When and How?

Treating HF Patients with ARNI s Why, When and How? Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor

More information

Disclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.

Disclosures. This speaker has indicated there are no relevant financial relationships to be disclosed. Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. And the Beat Goes On: New Medications for Heart Failure Alison M. Walton, PharmD, BCPS The Case of

More information

Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care

Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,

More information

Systolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine

Systolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine Systolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine Donna Mancini MD Choudhrie Professor of Cardiology Columbia University Speaker Disclosure Amgen

More information

2017 Summer MAOFP Update

2017 Summer MAOFP Update 2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases

More information

Disclosures for Presenter

Disclosures for Presenter A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,

More information

Rationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients

Rationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients Rationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients Javed Butler, MD, MPH, MBA Patrick H. Lehan Professor of Medicine Professor of Physiology Chairman,

More information

HEART FAILURE: PHARMACOTHERAPY UPDATE

HEART FAILURE: PHARMACOTHERAPY UPDATE HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis

More information

Outline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan

Outline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center

More information

What s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital

What s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital What s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital Disclosures I have no current or past relationships with commercial entities Learning objectives

More information

Sacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC

Sacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC Sacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC Head of Cardiology Medical Manager / CV Program CHUM Disclosure Statement Within the past two years: I have had an

More information

Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary

Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death

More information

Drugs acting on the reninangiotensin-aldosterone

Drugs acting on the reninangiotensin-aldosterone Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School

More information

From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group

From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF

More information

2/15/2017. Disclosures. Heart Failure = Big Problem. Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017

2/15/2017. Disclosures. Heart Failure = Big Problem. Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017 Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017 Julio A. Barcena, M.D. South Miami Heart Specialists Disclosures I have no relevant commercial relationships to

More information

Heart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist

Heart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE

More information

Checklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute

Checklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities

More information

How Do You Mend a Broken Heart: The New Agents to Treat HF Paradigm Shift or Just the Same Old Drugs?

How Do You Mend a Broken Heart: The New Agents to Treat HF Paradigm Shift or Just the Same Old Drugs? How Do You Mend a Broken Heart: The New Agents to Treat HF Paradigm Shift or Just the Same Old Drugs? Gregg C. Fonarow, MD FACC, FAHA, FHFSA Co-Chief UCLA Division of Cardiology Director, Ahmanson-UCLA

More information

New Winners in the World of Heart Failure. Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015

New Winners in the World of Heart Failure. Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015 New Winners in the World of Heart Failure Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015 Jessup 2014 Shaking Things Up 2003: FDA approved eplerenone for the treatment of heart failure

More information

Congestive Heart Failure: Outpatient Management

Congestive Heart Failure: Outpatient Management The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy

More information

Heart Failure: Current Management Strategies

Heart Failure: Current Management Strategies Heart Failure: Current Management Strategies CSHP Fall Education Session- September 30th, 2017 Carolyn MacKinnon & Tamara Matchett BscPharm, ACPR Candidates Objectives 1. Describe the pathophysiology &

More information

Online Appendix (JACC )

Online Appendix (JACC ) Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis

More information

Combination of renin-angiotensinaldosterone. how to choose?

Combination of renin-angiotensinaldosterone. how to choose? Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants

More information

Heart Failure Medical and Surgical Treatment

Heart Failure Medical and Surgical Treatment Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February

More information

1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?

1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure? Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,

More information

ACE inhibitors: still the gold standard?

ACE inhibitors: still the gold standard? ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University

More information

UPDATES IN MANAGEMENT OF HF

UPDATES IN MANAGEMENT OF HF UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion

More information

Initiating New Medications in the Management of Heart Failure

Initiating New Medications in the Management of Heart Failure Initiating New Medications in the Management of Heart Failure Sandra Oliver-McNeil DNP, MSN, ACNP-BC, CHFN Associate Professor (Clinical) Wayne State University College of Nursing Objectives The participant

More information

Updates in Congestive Heart Failure

Updates in Congestive Heart Failure Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk

More information

Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP

Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure Elizabeth Pogge, PharmD, MPH, BCPS, FASCP Disclosure Elizabeth Pogge reports no actual or potential conflicts of interest

More information

Known Actions of Digoxin

Known Actions of Digoxin Known Actions of Digoxin Hemodynamic effects in heart failure Increases cardiac output, no effect on blood pressure Decreases PCWP Increases LVEF (

More information

Highlight Session Heart failure and cardiomyopathies Michel KOMAJDA Paris France

Highlight Session Heart failure and cardiomyopathies Michel KOMAJDA Paris France Highlight Session 2014 Heart failure and cardiomyopathies Michel KOMAJDA Paris France # esccongress www.escardio.org/esc2014 HEART FAILURE AND CARDIOMYOPATHIES TOPIC 1 Drug Therapy TOPIC 2 Device Therapy

More information

HFpEF, Mito or Realidad?

HFpEF, Mito or Realidad? HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates July 2015 By Amy Friedman Wilson, PharmD Heart failure (HF) is a clinical condition in which ventricular filling or ejection of blood is structurally or functionally impaired. 1

More information

Aldosterone Antagonism in Heart Failure: Now for all Patients?

Aldosterone Antagonism in Heart Failure: Now for all Patients? Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C

More information

The ACC Heart Failure Guidelines

The ACC Heart Failure Guidelines The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA

More information

Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction

Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction Cardio-Metabolic Franchise Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction Randy L Webb, PhD Rutgers Workshop October 21, 2016 Heart

More information

Akash Ghai MD, FACC February 27, No Disclosures

Akash Ghai MD, FACC February 27, No Disclosures Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%

More information

Clinical Pearls Heart Failure Cardiology/New Drugs

Clinical Pearls Heart Failure Cardiology/New Drugs Clinical Pearls Heart Failure Cardiology/New Drugs Friday, September 9 th, 2016 Heidi Burres, PharmD, BCACP MTM Pharmacist Fairview Pharmacy Services Thank You to XYZ Event Sponsor(s): Wi-fi Information:

More information

Faiez Zannad. Institut Lorrain du Coeur et des Vaisseaux. CIC - Inserm

Faiez Zannad. Institut Lorrain du Coeur et des Vaisseaux. CIC - Inserm Faiez Zannad Institut Lorrain du Coeur et des Vaisseaux CIC - Inserm Disclosure Faiez Zannad Grants BG Medicine, Roche Diagnostics. Consultant/Steering committees/event committees/ Data safety Monitoring

More information

heart failure John McMurray University of Glasgow.

heart failure John McMurray University of Glasgow. A to Z of RAAS blockade in heart failure John McMurray BHF Cardiovascular Research Centre University of Glasgow. RAAS inhibition in CHF ACE inhibition in patients with low LVEF CHF CONSENSUS Enalapril

More information

Heart Failure New Drugs- Updated Guidelines

Heart Failure New Drugs- Updated Guidelines Heart Failure New Drugs- Updated Guidelines Eileen Handberg, PhD, ANP-BC, FAHA, FACC Professor of Medicine Division of Cardiovascular Medicine University of Florida Disclosures 1. 3 2. 6 3. 8 4. 11 Dunlay

More information

Management of chronic heart failure: update J. Parissis Attikon University Hospital

Management of chronic heart failure: update J. Parissis Attikon University Hospital Management of chronic heart failure: update 2015 J. Parissis Attikon University Hospital Disclosures: received honoraria for lectures from Servier, Pfizer, Novartis Discharges in Thousands Heart Failure

More information

REVIEW ARTICLE. Sacubitril/valsartan Use for the Hospitalist Mitchell Padkins 1, James Hart 1, Rachel Littrell 2

REVIEW ARTICLE. Sacubitril/valsartan Use for the Hospitalist Mitchell Padkins 1, James Hart 1, Rachel Littrell 2 Sacubitril/valsartan Use for the Hospitalist Mitchell Padkins 1, James Hart 1, Rachel Littrell 2 1 University of Missouri School of Medicine, Columbia, MO 2 Division of Cardiovascular Medicine, Department

More information

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor

LCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection

More information

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response

More information

ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD

ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD Karen Stout, MD FACC Professor, Medicine/Pediatrics University of Washington Seattle, WA USA No disclosures Case 35 year old man with

More information

Heart Failure: Combination Treatment Strategies

Heart Failure: Combination Treatment Strategies Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia

More information

Biomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed

Biomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed Biomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed Alan S. Maisel MD FACC Professor of Medicine, University of California, San Diego, Director, CCU and Heart Failure Program San Diego

More information

Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure

Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure June 28, 2016 Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure Linda C. Rogers, PhD, DABCC, FACB. Agenda Overview of the Natriuretic Peptides and Efficacy studies Similarities

More information

New Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition

New Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition New Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition Prakash Deedwania, MD, FACC, FACP, FCCP, FAHA Professor of Medicine, UCSF School of Medicine, Director,

More information

Practical considerations for the use of ARNI in CHF: clinical cases. J. Parissis, Heart Failure Clinic, University of Athens, Athens, Greece

Practical considerations for the use of ARNI in CHF: clinical cases. J. Parissis, Heart Failure Clinic, University of Athens, Athens, Greece Practical considerations for the use of ARNI in CHF: clinical cases J. Parissis, Heart Failure Clinic, University of Athens, Athens, Greece Disclosures: Research grants and honoraria for lectures from

More information

ARxCH. Annual Review of Changes in Healthcare. Entresto: An Overview for Pharmacists

ARxCH. Annual Review of Changes in Healthcare. Entresto: An Overview for Pharmacists Entresto: An Overview for Pharmacists David Comshaw, PharmD Candidate 2019 1 Gyen Musgrave, PharmD Candidate 2019 1 Suzanne Surowiec, PharmD, BCACP 1 Jason Guy, PharmD 1 1 University of Findlay College

More information

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Developed in Collaboration With the American Academy of Family Physicians, American College of Chest

More information

New Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD

New Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD New Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD Professor of Medicine, Cell Biology, Radiology and Surgery Director, The Howard Gilman Institute for Heart Valve Disease and the Schiavone

More information

Pharmacology. Update. Learning Objectives. Learning Objectives. for Advanced Practice Nurses

Pharmacology. Update. Learning Objectives. Learning Objectives. for Advanced Practice Nurses Pharmacology Update for Advanced Practice Nurses Trish Freeman, RPh, PhD Associate Professor, Pharmacy Practice and Science University of Kentucky College of Pharmacy University of Southern Indiana September

More information

9/10/ , American Heart Association 2

9/10/ , American Heart Association 2 Clyde W. Yancy, MD, MSc, MACC, FAHA, MACP Vice Dean, Diversity & Inclusion Magerstadt Professor of Medicine Professor of Medical Social Sciences Chief, Division of Cardiology Northwestern University, Feinberg

More information

INIBITORI NEPRILISINA

INIBITORI NEPRILISINA INIBITORI NEPRILISINA Marco Canepa, MD, PhD Università degli Studi di Genova Cardiologia, Ospedale Policlinico San Martino IRCCS marco.canepa@unige.it ARNI: ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITORS

More information

Contemporary Management of Heart Failure. Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium

Contemporary Management of Heart Failure. Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium Contemporary Management of Heart Failure Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium Disclosures I have no relevant relationships with commercial

More information

Optimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure

Optimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues

More information

Summary/Key Points Introduction

Summary/Key Points Introduction Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification

More information

DISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE

DISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New

More information

Heart Failure Update. Bibiana Cujec MD May 2015

Heart Failure Update. Bibiana Cujec MD May 2015 Heart Failure Update Bibiana Cujec MD May 2015 Disclosures Participation in clinical trial GUIDE IT (BNP in management of HF) Plan Review of new trials/ccs guidelines Management of heart failure: cases

More information

2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much?

2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much? 2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much? Dr. Shelley Zieroth University of Manitoba @ShelleyZieroth @CanHFSociety Disclosures Consulting/Advisory Board: Amgen, Astra

More information

State-of-the-Art Management of Chronic Systolic Heart Failure

State-of-the-Art Management of Chronic Systolic Heart Failure State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures

More information

Therapeutic Targets and Interventions

Therapeutic Targets and Interventions Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium

More information

Introduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL

Introduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL Introduction to Heart Failure Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL Disclosures No relevant financial relationships to disclose Objectives and Outline Define heart

More information

Disclosure Statement. Heart Failure: Refreshers and Updates. Objectives. CHF: Chronic Heart Failure. Definitions. Definitions 2/19/2018

Disclosure Statement. Heart Failure: Refreshers and Updates. Objectives. CHF: Chronic Heart Failure. Definitions. Definitions 2/19/2018 Disclosure Statement Heart Failure: Refreshers and Updates Tracy K. Pettinger, PharmD Clinical Associate Professor College of Pharmacy The planners and presenter of this presentation have disclosed no

More information

Heart Failure 101 The Basic Principles of Diagnosis & Management

Heart Failure 101 The Basic Principles of Diagnosis & Management Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence

More information

eplerenone 25, 50mg film-coated tablets (Inspra ) SMC No. (793/12) Pfizer Ltd

eplerenone 25, 50mg film-coated tablets (Inspra ) SMC No. (793/12) Pfizer Ltd eplerenone 25, 50mg film-coated tablets (Inspra ) SMC No. (793/12) Pfizer Ltd 08 June 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Neprilysin Inhibitor (Entresto ) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Neprilysin Inhibitor (Entresto ) Prime Therapeutics will review Prior

More information

Heart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis. More malignant than most cancers

Heart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis. More malignant than most cancers Patients in US (millions) Heart Failure (HF): Scope of the Problem 1 4 2 3.5 4. 1. 1991 21 237 US prevalence*: 5. million US annual incidence: 7, Annual mortality: 22,754 5-1% depending on severity Cost:

More information

Ejection Fraction in Patients With Chronic Heart Failure. Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction

Ejection Fraction in Patients With Chronic Heart Failure. Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction Keith Miller MD Diastolic Heart Failure Risk Factors Common Risk Factors Aging Female gender Obesity Hypertension Diabetes mellitus

More information

New Trials. Iain Squire. Professor of Cardiovascular Medicine University of Leicester. Chair, BSH

New Trials. Iain Squire. Professor of Cardiovascular Medicine University of Leicester. Chair, BSH New Trials Iain Squire Professor of Cardiovascular Medicine University of Leicester Chair, BSH BSH Heart Failure Day for Revalidation and Training 2017 Presentation title: New Trials Speaker: Iain Squire

More information

The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF)

The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF) The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF) 22 nd Annual Heart Failure 2018 an Update on Therapy April 21, 2018 Los Angeles, CA Barry Greenberg, M.D. Distinguished

More information

Use of Sacubitril/Valsartan in Heart Failure

Use of Sacubitril/Valsartan in Heart Failure Use of Sacubitril/Valsartan in Heart Failure & the PARADIGM-HF trial Sarah Mackenzie, PharmD student, University of Toronto Presentation Outline Overview of: Entresto PARADIGM-HF trial Critical Appraisal

More information

Saudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière

Saudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of

More information

2/3/2017. Objectives. Effective Heart Failure Management through Evidence Based Practice and Innovation

2/3/2017. Objectives. Effective Heart Failure Management through Evidence Based Practice and Innovation Effective Heart Failure Management through Evidence Based Practice and Innovation Jennifer Bauerly RN, CHFN, APRN-BC CentraCare Heart and Vascular Center Objectives Describe the scope and impact of heart

More information

ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure

ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg

More information

LXIV: DRUGS: 4. RAS BLOCKADE

LXIV: DRUGS: 4. RAS BLOCKADE LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations

More information

Behandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion

Behandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion Behandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion Professor Dr. med. Roger Hullin Leiter Programm für Schwere Herzinsuffizienz, VAD & Herztransplantation Suisse Romande Klinik

More information

Update on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy

Update on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Update on pharmacological treatment of heart failure Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Presenter Disclosures Dr. Maggioni : Serving in Committees of studies sponsored

More information

Sacubitril/Valsartan unter der Lupe Subgruppenanalysen, real world data,

Sacubitril/Valsartan unter der Lupe Subgruppenanalysen, real world data, Sacubitril/Valsartan unter der Lupe Subgruppenanalysen, real world data, praktische Erfahrungen michael.boehm@uks.eu M. Böhm Innere Medizin III (Kardiologie / Angiologie / Internistische Intensivmedizin)

More information

What s new in the 2017 heart failure guidelines. Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA

What s new in the 2017 heart failure guidelines. Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA What s new in the 2017 heart failure guidelines Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA Key points to remember 2017 guidelines recommend using natriuretic peptides as biomarkers to screen for heart

More information

Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -

Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology

More information

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National

More information

Heart Failure Therapies State of the Art 2017

Heart Failure Therapies State of the Art 2017 Heart Failure Therapies State of the Art 2017 Andrew J. Sauer, MD Assistant Professor Director, Center for Heart Failure Medical Director, Heart Transplantation UNOS Primary Transplant Physician asauer@kumc.edu

More information

Outline. Chronic Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G.

Outline. Chronic Heart Failure: Update on Effective Monitoring and Treatment. Heart Failure Epidemiology. Michael G. Chronic Heart Failure: Update on Effective Monitoring and Treatment Michael G. Shlipak, MD, MPH Professor of Medicine, UCSF Chief, Division of General Internal Medicine, SFVA Medical Center Scientific

More information

Heart Failure. GP Update Refresher 18 th January 2018

Heart Failure. GP Update Refresher 18 th January 2018 GP Update Refresher 18 th January 2018 Heart Failure Dr. Alexander Lyon Senior Lecturer and Consultant Cardiologist Clinical Lead in Cardio-Oncology Royal Brompton Hospital, London UK President of British

More information

Introduction: Clinical Trials: Assessing Safety and Efficacy for a Diverse Population

Introduction: Clinical Trials: Assessing Safety and Efficacy for a Diverse Population Introduction: Clinical Trials: Assessing Safety and Efficacy for a Diverse Population FDA and JHU-CERSI White Oak, Maryland Wednesday, December 2, 2015 Keith C. Ferdinand, MD, FACC,FAHA,FNLA,FASH Professor

More information

Disclosure of Relationships

Disclosure of Relationships Disclosure of Relationships Over the past 12 months Dr Ruilope has served as Consultant and Speakers Bureau member of Astra-Zeneca, Bayer, Daiichi-Sankyo, Menarini, Novartis, Otsuka, Pfizer, Relypsa, Servier

More information

ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR

ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR ESC Guidelines for diagnosis and management of HF 2012: What s new? John Parissis, MD Athens, GR Disclosures ALARM INVESTIGATOR RESEARCH GRANTS BY ABBOTT USA AND ORION PHARMA The principal changes from

More information

HFpEF 2016 : Comorbidities and Outcomes

HFpEF 2016 : Comorbidities and Outcomes HFpEF 2016 : Comorbidities and Outcomes Christopher M. O Connor, MD, FACC CEO and Executive Director, Inova Heart and Vascular Institute Professor of Medicine, Duke University Editor in Chief, JACC: Heart

More information

Heart Failure with Preserved EF (HFPEF) Epidemiology and management

Heart Failure with Preserved EF (HFPEF) Epidemiology and management Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se

More information

RAS Blockade Across the CV Continuum

RAS Blockade Across the CV Continuum A Summary of Recent International Meetings RAS Blockade Across the CV Continuum Copyright New Evidence Presented at the 2009 Congress of the European Society of Cardiology (August 29-September 2, Barcelona)

More information

Update in Congestive Hear Failure DRAGOS VESBIANU MD

Update in Congestive Hear Failure DRAGOS VESBIANU MD Update in Congestive Hear Failure DRAGOS VESBIANU MD Case 58 yo AAM c/o shortness of breath for 3 weeks. Used to walk one mile per day and now he has noticed that he gets short of breath after 2 blocks.

More information